Back

First-in-human gene editing for lipid lowering: the initial results

Cardiovascular Research

30 March 2024
Organised by: Logo
Read full article
ESC Journals

Contributors

Simon Tual-Chalot
Simon Tual-Chalot

Author

Konstantinos Stellos
Konstantinos Stellos

Author

University of Heidelberg Heidelberg , Germany

You may be interested in
thumbnail
Congress Presentation
Can gene editing address unmet need in dyslipidaemia?
30 August 2025
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021
thumbnail
Practice Tools
How to manage blood cholesterol in primary and secondary prevention
16 May 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources